BACKGROUND: Recent reports have suggested that erlotinib therapy after gefitinib failure
requires optimal patient selection to obtain clinical benefits in relapsed non-small cell lung …

Background Several clinical trials showed that erlotinib was effective after the failure of
gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to …

Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …

BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …

Purpose To evaluate the efficacy and safety of erlotinib in advanced non-small-cell lung
cancer after failure of gefitinib treatment. Patients and methods Patients with advanced or …

PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …

Erlotinib and gefitinib are among the most widely researched, used and available
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …

Objective Few treatment options are available for advanced non-small cell lung cancer
(NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line …

Background Gefitinib and erlotinib are two orally active epidermal growth factor receptor
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …

Introduction The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
gefitinib and erlotinib are gaining an increasing role in the management of advanced non …